17th Annual HIV Conference Archive
Orlando - Florida
March 28-29, 2008
Slides/Resource Materials
Medication/Pharmacy- Related Topics One session in each time slot has been identified as offering the medication-related information pharmacists need most. |
| Friday, March 28, 2008 |
|
Antiretroviral (ARV) Therapy Management
Jennifer Janelle, MD The treatment of HIV has changed substantially over the past 15 years and multiple new medications have been approved to add to the arsenal for treatment of those infected with HIV. This session will include a review of the natural history of HIV, the target sites for those drugs with current FDA approval, and the current DHHS guidelines for HIV therapy – including timing of initiation of therapy, indications for changing therapy, and consideration of co-morbid conditions. |
| Interpretation of HIV Clinical Trial Data Todd Wills, MD This session will review the various types of clinical trials encountered by HIV clinicians. The strengths and weaknesses of various study designs will be discussed. Special consideration will be made of the ethical limits on placebo-controlled trials and the changes in trial design which have resulted. Advanced topics will include and analysis of Active-Control trials, non-inferiority trials, and the role of genotypic and phenotypic sensitivity scores in the review of new agents. |
New Drugs and New Hope This presentation will review the newer antiretroviral agents, including important side effects, dosing, suggested recommendations for appropriate timing, drug-drug interactions, and relevant studies regarding efficacy of these products. |
| Saturday, March 29, 2008 |
HIV & Tuberculosis 2008 David Ashkin, MD TB is the leading cause of death among HIV-infected individuals worldwide. Diagnosing and treating HIV-infected individuals for TB infection and disease can pose challenges to the clinician. Newly identified extensively drug resistant strains of TB are threatening to destabilize TB control efforts globally. In this session, the speaker will review treatment of latent TB infection and active TB disease. The speaker will also discuss issues such as timing of initiation of antiretroviral therapy in relation to TB therapy, immune reconstitution/inflammatory response syndrome, drug-drug interactions, and resistance. |
Current Issues with Sexually Transmitted Infection Management for the HIV Provider John Toney, MD Accurate identification of STDs and effective clinical management strategies based on current treatment guidelines are a major component in the effort to advance HIV prevention strategies. Routine STD screening using diagnostic studies leads to effective diagnosis and treatment. Clinical guidance based on open dialog includes education and counseling to reduce the risk of acquiring STDs along with evaluation, treatment and counseling of sexual partners. |
| Drug Interactions Linda Kam, PharmD This session will outline common drug interactions encountered in the management of HIV infection including medications that may be co-administered in the management of a patient’s other disease states. A discussion on how drug interactions are used to maximize HIV therapy will be portrayed. Mechanisms used to manage commonly encountered antiretroviral drug interactions will be introduced. |
|
Why is this Combination Failing?
HIV Resistance The advances in the science of HIV allow us to identify the mutations present when a patient fails antiretroviral therapy. The resistance tests available today are genotype and phenotype. During this session we will learn the basics of these tests, how/when to use them in clinical practice and how to interpret them. We will also review the most common mutations related to the specific antiretrovirals. |
|
Triple Diagnosis: HIV, Substance
Abuse & Mental Illness Co-occurring mental illness and substance use disorders are recognized as dual diagnosis in psychiatric services. When they co-occur among people living with HIV/AIDS it is referred to "triply diagnosed". Patients with HIV infection, psychiatric and co-morbid substance abuse disorders have been linked with negative outcomes, including HIV-related morbidity and mortality, poor medication adherence, inadequate medical treatment, lower quality of life, and risky sexual behaviors. They are more vulnerable than other medically ill populations because of the level of disease burden they experience and poor health outcomes. This session will focus on the HIV prevalence in people with co-morbid psychiatric and substance abuse diagnoses, substance abuse assessment and referral, treatment options for the triply diagnosed and interactions between ARVs and psychotropic agents and drugs of abuse. |
